Immunovia AB (publ) (IMMNOV.ST)

Nasdaq Stockholm · Financial statements, TTM figures and earnings dates

In fiscal year 2023 (ended December 31, 2023), Immunovia AB (publ) reported revenue of SEK 1.8M and net income of −SEK 309.4M. Annual financial statements are available for fiscal years 2021 to 2023, taken from the company's ESEF annual reports (IFRS).

Open interactive financials →

Key financials

SEK	FY2023 2023-12-31	FY2022 2022-12-31	FY2021 2021-12-31
Income statement
Revenue	SEK 1.8M	SEK 1.2M	SEK 956.0K
Operating income	−SEK 296.5M	−SEK 191.2M	−SEK 166.6M
Net income	−SEK 309.4M	−SEK 168.1M	−SEK 156.0M
Diluted EPS	−SEK 7.95	−SEK 7.43	−SEK 6.89
Cash flow
Operating cash flow	−SEK 147.1M	−SEK 175.6M	−SEK 152.6M
Capital expenditure	SEK 0	SEK 1.3M	SEK 3.1M
Free cash flow	−SEK 147.1M	−SEK 176.8M	−SEK 155.7M
Balance sheet
Cash and equivalents	SEK 76.8M	SEK 106.0M	SEK 287.4M
Total assets	SEK 98.7M	SEK 300.6M	SEK 493.8M
Total liabilities	SEK 31.7M	SEK 56.8M	SEK 59.9M
Shareholders' equity	SEK 67.0M	SEK 243.8M	SEK 433.9M

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full IMMNOV.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open IMMNOV.ST financials →